key: cord-0943557-sexxdoj7
authors: Muzio, Lorenzo Lo; Bizzoca, Maria Eleonora
title: Vaccine or Monoclonal therapy: which is winning weapon against COVID-19?
date: 2021-07-07
journal: J Glob Antimicrob Resist
DOI: 10.1016/j.jgar.2021.05.021
sha: f7d5b275af73c13cd1cfcf188aab0d142fdcde0c
doc_id: 943557
cord_uid: sexxdoj7

nan

SARS-CoV-2 pandemic is causing thousands of deaths and blocking activities of the global community. All hopes are now put on vaccines, such as BioNTech (Pfizer), Oxford (AstraZeneca), Moderna, Sinovac, CanSino, Sinopharma, Novavax, etc. However, a new problem is emerging: the possibility of reinfection for healed subjects. Recent reports outlined cases of SARS-CoV-2 reinfection from different countries such as US, Ecuador, Hong Kong, Belgium [1] . It is necessary to verify if all these cases are really reinfection because the possibility of reinfection could drastically reduce the effectiveness of the vaccination campaign in progress and affect government and public health policy decisions in the coming months. Protective, sustainable and long-lasting immunity following COVID-19 infection is uncertain, but it is essential for the efficacity of vaccine strategy.

For some viruses, the first infection can provide lifelong immunity, for seasonal coronaviruses protective immunity is short-lived. How long does coronavirus immunity last after testing positive? This is the question that all experts have been asking themselves since the beginning of the pandemic and several studies are now trying to answer. A recent report studied the resistance of immune memory in 185 patients affected by Sars-Cov2 [2] . While antibodies and T lymphocytes tended to decrease slightly over time, B lymphocytes were observed to have grown in number [2] . In people affected by Sars-Cov-2, the immune response modulated by IgM and IgG antibodies shows an activation starting from the seventh day following the infection, up to a very rapid increase in the number of total antibodies between the second and third week, even close to 100% [2] . A small percentage of patients do not have it, probably due to the low amount of virus to which they are exposed [2] . B lymphocytes or memory cells "remember" the viral infection and, if re-exposed to the virus, are able to trigger a protective immune response through the rapid production of antibodies [3] . A recent study verified that all patients continued to have memory B cells that recognized one of virus components, till to eight months after infection [3] . These results give hope for the effectiveness of any coronavirus vaccine, and also explain why there have been very few cases of reinfection among the millions of those who were positive worldwide [3] . Another problem Lilly pointed out that its s neutralizing antibody bamlanivimab prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents [6] . Only four COVID-19-related deaths occurred in the study, and all were in nursing home residents in the placebo group [6] . In conclusions recent studies pointed out: a small percentage of patients do not have immune protection after SARS-CoV-2 infection, probably due to the low amount of virus to which they are exposed, so can a patient recovered from covid-19 get sick again? Could this happen also with vaccination? Reinfection cases with SARS-CoV-2 proved that levels of immunity are not 100% for all individuals. Even though several vaccines are ready, the presence of more than 80 genotypical variants of the virus, possibility of reinfection, and short duration of seropositivity for neutralizing antibodies raise the concern that vaccination may not result in an effective and longterm immunity against SARS-CoV-2. Furthermore, immunoglobulin levels may not correlate with viral shedding and risk of transmissibility of SARS-CoV-2. Some considerations arise from all these data. Firstly, several studies reinforce the possibility that vaccines will work for a long time with a very optimistic result. Secondly, it is necessary to vaccinate even those who have already had Covid-19, although later than all the others. Thirdly, for many months it will be necessary to continue to observe all the prescriptions adopted in order to limit the spread of the virus and any new variants. Fourthly, all these factors raise concerns that eliminating SARS-CoV-2 pandemic may not be as feasible as once assumed and that we must rely more on prevention of transmission until more aspects of the virus and its pathogenicity are discovered. If we want to win the war against SARS-CoV-2 is necessary to identify possible innovative treatment alternatives, such as monoclonal antibodies [7] , nanotechnology applications, such as viral inactivators, including cellular nanosponges in order to reduce viral adhesion [8] , or the treatment of Personal Protective Equipment (PPE) with charged metallic (such as Cu, Ag, Fe, Zn among others) nanoparticles, which seems to result in the release of antiviral agents (i.e., reactive oxygen species)able to inhibit viral entry in host cells, by means of interactions with cell receptors [9] .

Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain

Immunological memory to SARS-CoV-2 assessed for greater than six months after infection. BioRviX

Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv

SARS-CoV-2 reinfection by the new Variant of Concern (VOC) P.1 in Amazonas, Brazil

Monoclonal antibodies can prevent COVID-19-but successful vaccines complicate their future

Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19

Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity

Can Nanotechnology and Materials Science Help the Fight against SARS-CoV-2? Nanomaterials (Basel)